NCT ID NCT06066424

Title Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells

in Patients With Advanced Solid Tumors (TROPIKANA)

 Phase
 Phase 1

 Date Added
 2023-10-04

Location Texas, United States

Prior IO Allowed Yes
CRC-directed No

Status Recruiting

Drugs Cyclophosphamide, Fludarabine Phosphate, Rimiducid, TROP2-CAR-NK Cells

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06065371

Title Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on

Standard Therapy

 Phase
 Phase 1

 Date Added
 2023-10-03

Location Michigan, United States

Prior IO Allowed Yes
CRC-directed Yes
Status Recruiting

Drugs capecitabine, Sacituzumab govetican

Tags MSS/ MMRp

NCT ID NCT06060704

Title Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

PhasePhase 2Date Added2023-09-29LocationChinaPrior IO AllowedYesCRC-directedYesStatusRecruiting

Drugs Bevacizumab, Envafolimab, Trifluridine/Tipiracil, Avastin, Lonsurf

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06055439

Title A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

 Phase
 Phase 1, Phase 2

 Date Added
 2023-09-26

Location Georgia, United States

Illinois, United States Pennsylvania, United States Tennessee, United States

Prior IO Allowed Yes

CRC-directed Yes

Status Recruiting

Drugs

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06047015

Title Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer

Phase 1

Date Added 2023-09-21

Location

Prior IO Allowed Yes
CRC-directed Yes

Status Not yet recruiting

Drugs

Tags MSS/ MMRp

NCT ID NCT06043713

Title Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors

(FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers

With KRAS G12V Mutations

 Phase
 Phase 1

 Date Added
 2023-09-21

Location Washington, United States

Prior IO Allowed Yes
CRC-directed No

Status Suspended

Drugs Bendamustine, Cyclophosphamide, Fludarabine

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06039202

Title Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With

Relapsed and/or Refractory Metastatic Colorectal Cancer

 Phase
 Phase 2

 Date Added
 2023-09-15

Location

Prior IO Allowed Yes
CRC-directed Yes

Status Not yet recruiting

Drugs CA102N, TAS-102

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06039384

Title A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C

Mutation

 Phase
 Phase 1

 Date Added
 2023-09-15

Location California, United States

Colorado, United States Michigan, United States Texas, United States Virginia, United States

Italy Spain

United Kingdom

Prior IO Allowed Yes
CRC-directed Yes

Status Terminated

Drugs Adagrasib, INCB099280

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06034860

Title Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer

Types

 Phase
 Phase 1

 Date Added
 2023-09-13

Location California, United States

Indiana, United States Missouri, United States New York, United States Virginia, United States

Prior IO Allowed Yes
CRC-directed No

Status Active, not recruiting

Drugs MT-8421, Nivolumab, Opdivo

Tags MSI-H/ MMRd

NCT ID NCT06026774

Title Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System

Neoplasms

PhasePhase 1Date Added2023-09-07LocationChinaPrior IO AllowedYesCRC-directedYes

Status Recruiting

Drugs

Tags MSI-H/ MMRd, MSS/ MMRp